fbpx
QQQ
+ 1.21
343.16
+ 0.35%
DIA
+ 0.15
338.63
+ 0.04%
SPY
+ 0.95
419.91
+ 0.23%
TLT
-0.13
143.42
-0.09%
GLD
-0.23
167.18
-0.14%

UPDATE: Stifel Initiates Coverage on Celladon Corporation with Buy Rating, $16 PT as Novel Gene Therapy Could Revolutionize Heart Failure Treatment

by
February 24, 2014 10:02 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

In a report published Monday, Stifel analyst Brian Klein initiated coverage on Celladon Corporation (NASDAQ: CLDN) with a Buy rating and $16.00 price target.

In the report, Stifel noted, “We are initiating coverage of Celladon Corporation (CLDN) with a Buy rating and $16 target price. Mydicar is a one-time infusion of a viral vector that transfers a SERCA2a gene into heart muscle cells with the intention of improving calcium regulation and improving function.”

Celladon Corporation closed on Friday at $7.57.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

Wedbush Just Downgraded Celladon To Neutral And Slashed Its PT By $26

H.C. Wainwright Initiates Coverage On Celladon, Cites Impressive Trial Results For Heart Failure Therapy